NextCure Q3 net loss $11.5M, cash $75.3M; plans LNCB74 IND by Q4 2024

NextCure, Inc.

2024-Q3 EPS reported -$1.58

Net loss of $11.5M for Q3 2024, vs $14.3M in Q3 2023; R&D expense down to $8.8M.
Cash, cash equivalents, and marketable securities $75.3M as of Sep 30, 2024; expected runway into H2 2026.
LNCB74 (B7-H4 ADC) IND planned by Q4 2024; preclinical data at SITC in November.
NC410 combo trial concluding, seeking partner; ovarian ICI-naïve response rate 25% (5/20) and CRC MSS 8.3% (3/36) PRs at 100 mg.
Preclinical NC181 (Alzheimer's) and NC605 (osteogenesis) also seeking partner or financing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.